# Avalon Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avalon-pharmaceutical

- Industry: Biotechnology
- Headquarters: Germantown, US
- Website: www.avalonrx.com
- Total disclosed funding: $80M
- Latest round: Series B (Dec 17, 2001)
- Investors on record: 14

## About

Avalon Pharmaceutical, Inc. is a healthcare company focused on developing advanced therapeutic treatments and innovative technology platforms to enhance patient care and clinical outcomes.Founded in 1999 in Germantown, US, Avalon Pharmaceutical, Inc. specializes in healthcare solutions, particularly innovative therapeutic treatments. The company completed its IPO on September 29, 2005, and has engaged in 8 total deals since its inception. The founder's specific history is not provided.AvalonRx specializes in developing innovative healthcare solutions, focusing on advanced therapeutic treatments and healthcare technology platforms. The company's offerings include proprietary therapies for specific medical conditions and digital health tools that enhance patient engagement and streamline clinical workflows. AvalonRx caters to hospitals, outpatient clinics, and research institutions in North America and Europe, with a recent expansion into the United States, Canada, Germany, and the United Kingdom.In 2008, AvalonRx reported revenue of USD 311,000 with an EBITDA of USD -20,491,000. The company generates revenue through partnerships with healthcare providers and direct sales to clients, utilizing a subscription model for its digital health platforms and collaborating with distributors for a broader market reach.Avalon Pharmaceutical, Inc. aims to launch new products and expand into additional markets. The company is targeting new geographic regions for growth, particularly in North America and Europe, following its IPO in September 2005. Recent funding will be utilized to support these initiatives, enhancing their product development and market reach.

## Funding rounds

- Series B, Dec 17, 2001, $70M — PineBridge Investments, EuclidSR Partners, Forward Ventures, OrbiMed Advisors, Oxford Bioscience Partners, RBC Capital Markets, Gimv, CDPQ, KBL Healthcare Ventures, GeneChem, Tekla Capital Management, Emerging Technology Partners, Maryland Department of Business and Economic Development, Canadian Medical Discoveries Fund Inc.
- Series A, Jun 1, 2000, $10M — Forward Ventures, Oxford Bioscience Partners, Gimv, Emerging Technology Partners, Maryland Department of Business and Economic Development

## Investors

- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series A, Series B
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series A, Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A, Series B
- Emerging Technology Partners (https://capitalatlas.ai/funds/emerging-technology-partners) — Series A, Series B
- Maryland Department of Business and Economic Development — Series A, Series B
- PineBridge Investments (https://capitalatlas.ai/funds/pinebridge-investments) — Series B
- EuclidSR Partners (https://capitalatlas.ai/funds/euclidsr-partners) — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- RBC Capital Markets (https://capitalatlas.ai/funds/rbc-capital-markets) — Series B
- CDPQ — Series B
- KBL Healthcare Ventures (https://capitalatlas.ai/funds/kbl-healthcare-ventures) — Series B
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series B
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series B
- Canadian Medical Discoveries Fund Inc. — Series B